Table 5.

Summary of BESS Quality of Life Assessmentby symptom clusters according to the treatments

Symptom Cluster	Tamoxifen(20mg/day) (N=14)		4-OHT gel(4mg/day) (N=12)
	Mean ± SD	P*	Mean ± SD	P*	P†
Cognitive
baseline	0.62 ± 0.61		0.61 ± 1.11		0.54
post-treatment	0.71 ± 1.18		0.69 ± 1.20
Changes from baseline	0.10 ± 0.86	0.99	0.08 ± 0.47	0.81	0.64
Body pain
baseline	0.76 ± 1.12		0.56 ± 0.94		0.49
post-treatment	1.19 ± 1.11		0.58 ± 0.74
Changes from baseline	0.43 ± 0.92	0.11	0.03 ± 0.61	0.78	0.27
Vasomotor
baseline	0.33 ± 0.45		0.19 ± 0.41		0.35
post-treatment	0.88 ± 1.26		0.53 ± 0.73
Changes from baseline	0.55 ± 1.05	0.06	0.33 ± 0.64	0.13	0.83
Gastrointestinal
baseline	0.12 ± 0.31		0.00 ± 0.00		0.18
post-treatment	0.02 ± 0.09		0.06 ± 0.13
Changes from baseline	−0.10 ± 0.24	0.50	0.06 ± 0.13	0.50	0.049
Sexual problems
baseline	0.32 ± 0.72		0.42 ± 0.67		0.55
post-treatment	0.11 ± 0.40		0.25 ± 0.5
Changes from baseline	−0.21 ± 0.54	0.25	−0.17 ± 0.81	0.53	0.48
Bladder
baseline	0.14 ± 0.36		0.17 ± 0.39		0.87
post-treatment	0.25 ± 0.33		0.25 ± 0.40
Changes from baseline	0.11 ± 0.49	0.59	0.08 ± 0.19	0.50	0.67
Body image
baseline	0.68 ± 0.77		0.63 ± 0.83		0.55
post-treatment	0.64 ± 0.89		0.75 ± 1.06
Changes from baseline	−0.04 ± 0.87	0.92	0.13± 0.53	0.75	0.26
Vaginal
baseline	0.00 ± 0.00		0.14 ± 0.26		0.052
post-treatment	0.07 ± 0.19		0.14 ± 0.33
Changes from baseline	0.07 ± 0.19	0.50	0.00 ± 0.14	0.75	0.08

^*Wilcoxon signed-rank tests were used for the changes from baseline within a treatment group.

^†Wilcoxon rank-sum tests were used for baseline, and the changes from baseline between treatment groups.